Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Wallstrip: United Therapeutics Corp. (UTHR)
- Dr. Rothblatt started a company to save her daughter's life. United Therapeutics Corp. UTHR
- Videos 2008-10-22
Additional Resources
- Data from Pivotal Phase III Studies of Gilead's Letairis® for Pulmonary Arterial Hypertension in Patients with WHO Functional Class II or III Symptoms Published in Circulation
- FOSTER CITY, Calif. -- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that data from the pivotal Phase III ARIES-1 and ARIES-2 studies of Letairis([R]) were published in Circulation online before print. Letairis (ambrisentan 5 mg and 10 mg tablets) is indicated as a once-daily treatment for pulmonary arterial hypertension PAH (WHO...
- Research articles 2008-05-29
- Gilead Submits New Drug Application To U.S. FDA for Ambrisentan for the Treatment of Pulmonary Arterial Hypertension
- FOSTER CITY, Calif. -- Gilead Sciences, Inc. (Nasdaq:GILD) today announced the submission of a New Drug Application NDA to the U.S. Food and Drug Administration FDA for marketing approval of ambrisentan (5 mg and 10 mg) for the once-daily treatment of pulmonary arterial hypertension PAH. The application is supported by...
- Research articles 2006-12-18
- Actelion Receives Frost & Sullivan 2007 North American Pulmonary Arterial Hypertension Market Leadership Award
- PALO ALTO, Calif. -- Frost & Sullivan today announced that it has awarded the 2007 North American Pulmonary Arterial Hypertension PAH Market Leadership of the Year Award to Actelion Pharmaceuticals US, Inc. According to Frost & Sullivan's research, Actelion is the key leader in the U.S. PAH market. Actelion's product...
- Research articles 2007-09-20
- Biogen Idec and mondoBIOTECH Sign Collaboration and Licensing Agreement to Develop and Commercialize Aviptadil for Pulmonary Arterial Hypertension
- CAMBRIDGE, Mass., and Switzerland -- Biogen Idec (NASDAQ: BIIB) and mondoBIOTECH AG, a private Swiss biotechnology company, today announced the signing of an exclusive collaboration and license agreement for Biogen Idec to develop, manufacture and commercialize Aviptadil, a clinical compound for the treatment of Pulmonary Arterial Hypertension PAH.
- Research articles 2006-09-14
- Myogen Reports Results for the Integrated Analysis of ARIES-1 and ARIES-2 Pivotal Trials of Ambrisentan in Pulmonary Arterial Hypertension; Significant Improvements Observed for All Primary and Secondary Endpoints
- DENVER -- Myogen, Inc. (Nasdaq: MYOG) today announced results for the integrated analysis of ARIES-1 and ARIES-2, the pivotal Phase 3 trials evaluating ambrisentan, an oral endothelin receptor antagonist ERA, in pulmonary arterial hypertension PAH. The integrated analysis was prospectively defined as a supportive analysis of the ARIES trials' results...
- Research articles 2006-05-03
- Toray and Astellas Pharma Announce of the Acquisition of Marketing Approval for the Pulmonary Arterial Hypertension Agent Careload® LA Tablets 60mu/g in Japan
- Tokyo, Japan, Oct 22, 2007 - JCN Newswire - Toray Industries Inc. (TSE: 3402) and Astellas Pharma Inc. (TSE: 4503) today announced that Toray has obtained marketing approval for its oral PGI2 derivative prolonged release, CareloadR LA Tablets 60mu/g (generic name: beraprost sodium), to be indicated for pulmonary arterial hypertension...
- Research articles 2007-10-23
- Pivotal Pulmonary Arterial Hypertension Study Concludes That Early Detection and Intervention is Key to Delay Disease Progression
- Actelion Pharmaceuticals Canada announced today that data presented at the recent European Cardiology Society meeting, and also published in The Lancet(1) show that, even in mildly symptomatic pulmonary arterial hypertension PAH patients (WHO functional class II - WHO FC II), the disease progresses very rapidly, such that patients can worsen...
- Research articles 2008-09-23
- PFIZER INC - Research Update.
- Published Study Shows Benefits of Revatio Sildenafil Citrate in Patients With Pulmonary Arterial Hypertension ...
- Research articles 2005-11-17
- Regulatory Application.
- Pfizer Submits Regulatory Filings for Revatio as a Treatment for Pulmonary Arterial Hypertension NEW...
- Research articles 2004-12-06
- PFIZER INC - Regulatory Approval - Product Approval.
- Pfizer's Revatio Receives European Approval to Treat Pulmonary Arterial Hypertension ...
- Research articles 2005-11-04
- FDA Calendar Updates: United Therapeutics, Roche
- Mike Havrilla submits: Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of 288 entries as of 7/30/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA....
- External links 2009-07-30
- Novel Concept of Measuring Percutaneous Oxygen Saturation Monitor during Cardio-Pulmonary Bypass
- During cardiopulmonary bypass CPB, oxygenation is often only intermittently monitored via arterial blood gas analysis ABG. CPB may not generate sufficient pulsations for pulse oximetry to work continuously. These researchers studied the use of external oscillations to produce accurate SpO2 measurements during CPB. Sampling of ABG every 30 minutes is...
- White papers 2003-11-04
- Predix Pharmaceuticals Obtains Special Protocol Assessment for PRX-00023 Pivotal Study in Anxiety; Predix Also Initiates Phase Ib Clinical Trial for PRX-08066 in Pulmonary Arterial Hypertension
- LEXINGTON, Mass. & RAMAT GAN, Israel -- Predix Pharmaceuticals, a drug discovery and development company, announced today that under the Special Protocol Assessment process, it has reached final agreement with the United States Food and Drug Administration FDA on the design and statistical analysis plan of its first pivotal study...
- Research articles 2005-11-30
- ICOS Corporation and Texas Biotechnology Corporation Initiate a Pivotal Trial in Pulmonary Arterial Hypertension
- Business Editors & Health Writers
- Research articles 2001-05-30
- FDA Advisory Committee Votes Unanimously to Recommend Approval of Tracleer for Treatment of Pulmonary Arterial Hypertension
- Business and Health Editors
- Research articles 2001-08-10
- U.S. Food and Drug Administration Approves Gilead's Letairis™ 5 mg and 10 mg Tablets for the Once-Daily Treatment of Pulmonary Arterial Hypertension in Patients with WHO Functional Class II or III Symptoms
- Gilead Also Announces Launch of Gilead([TM])Solutions, a Comprehensive Access Program
- Research articles 2007-06-15
- Silver Spring-based United Therapeutics Corp. gets Japanese
- United Therapeutics Corp., of Silver Spring, a developer of pharmaceuticals to combat chronic and life-threatening cardiovascular, infectious and cancer diseases, said it signed an agreement with Mochida Pharmaceutical Co. Ltd., for the exclusive distribution in Japan of United Therapeutics' Remodulin, a drug used to treat pulmonary arterial hypertension, a dangerous...
- Research articles 2007-03-28
- ICOS Corporation Reports Results for 2005 First Quarter; Tadalafil to be Evaluated in a Pivotal Clinical Study in Pulmonary Arterial Hypertension
- BOTHELL, Wash. -- ICOS Corporation (Nasdaq:ICOS) today released its financial results for the three months ended March 31, 2005 and summarized recent events.
- Research articles 2005-05-05
- GlaxoSmithKline and Myogen Announce Pulmonary Arterial Hypertension Partnership; GlaxoSmithKline to Commercialize Ambrisentan in All Territories Outside of the U.S
- DENVER & LONDON -- Myogen Receives Flolan Rights in U.S. and Will Launch Commercial Operations in Q2 '06
- Research articles 2006-03-06
- << Previous
- page 1 of 1
- Next >>
Presented by American Express